Cite

HARVARD Citation

    Gärtner, J. et al. (2022). 113  Benefit-risk of ofatumumab in treatment-naïve early relapsing multiple sclerosis patients. Journal of neurology, neurosurgery and psychiatry. 93 (6), p. A136. [Online]. 
  
Back to record